SeekPeptides members often ask about optimal product selection and sequencing
Funded by drug manufacturer Novo Nordisk, the study adds to the growing list of medical conditions that could potentially benefit from semaglutide, which, apart from its broad use in weight loss and diabetes management, is also suggested to lower risks for conditions such as dementia, mental health issues, and heart disease
10.1016/S0140-6736(23)01200-X
Novo Nordisk, a pharmaceutical company based in Denmark, made the first of the recent blockbuster drugs, Ozempic, which emerged on the scene as a drug for people with diabetes
Some emerging research suggests that metabolic improvements associated with GLP-1 therapy might theoretically be beneficial for cancer survivors